

Anti-Obinutuzumab Polyclonal Antibody

Summary

Catalog No.	PAC90701
Host species	Rabbit
Specificity	The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Tested applications	ELISA: 1:4000-1:8000
Immunogen	Obinutuzumab
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	0.21 mg/ml
Clonality	Polyclonal
Isotype	IgG
Applications	ELISA
Target	Rabbit polyclonal to Gazyva.
Purification	Purified by antigen affinity column.
Accession	CAS: 949142-50-1
Stability and Storage	The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Note	Antibodysystem can customize this product per customer's request including product size, buffer components, etc. For research use only.

Background

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naïve patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Data Image
